You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

Citation Tools

Article menu

Download PDFPDF

XML
Original research
Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ahmed M, Putri C, Quhill H, et al
Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series
BMJ Open Ophthalmology 2020;5:e000484. doi: 10.1136/bmjophth-2020-000484